IMF Videos Search Content For Healthcare Professional (182) Healthcare Provider (182) Series - Any - About the IMF (2) ASCO/EHA (163) ASH (230) Ask Dr. Durie (247) Black Swan Research Initiative (7) Community Workshops (33) Emerging Therapies (20) Facebook Live (21) Health Equity (16) IMF History (4) IMWG (13) Inspirational (16) Living Well with Myeloma (34) Myeloma in a Minute (19) Myeloma Made Simple (15) Myeloma University (12) NLB Webcasts (1) Patient & Family Webinar (27) Q&A (19) Recent News and Developments (4) Treatments (4) Trending Searches in Myeloma (1) Topics Clinical Trials (136) Financial Considerations (1) Frontline Therapy (34) Health Equity (10) Inspirational Stories (1) Lab & Imaging Tests (26) Lifestyle (4) Mental & Emotional Health (1) Public Policy & Advocacy (1) Recorded Webinars (2) Relapse/Refractory Myeloma (80) Research Updates (151) Symptom Management (8) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (31) High-Risk Myeloma (29) High-risk Smoldering Myeloma (13) Late Relapse (4–6 Lines of Therapy) (63) MGUS (18) Newly Diagnosed (Pre-Treatment or First Treatment) (52) Smoldering Myeloma (22) Types of Therapy Immunomodulatory drugs (IMiDs) (57) Immunotherapies (CAR T; BiTE, etc.) (60) Monoclonal antibodies (49) Proteasome inhibitors (50) Stem cell transplant (38) Steroids (21) Supportive Care (17) Year Published 2026 (7) 2025 (24) 2024 (23) 2023 (21) 2022 (34) 2021 (27) 2020 (18) 2019 (32) 2018 (30) 2017 (5) 2016 (3) 2015 (6) Trusted Voices Dr. María-Victoria Mateos (8) Dr. Saad Usmani (4) Dr. Shaji Kumar (4) Dr. Brian GM Durie (3) Dr. Joseph Mikhael (3) Dr. Sagar Lonial (1) Dr. Sigurður Kristinsson (1) Dr. Tom Martin (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy December 11, 2019 ASH Valutazione MRD mediante citometria a flusso multiparametrico e NGS nella sperimentazione Forte December 11, 2019 ASH Estrategia curativa (GEM-CESAR) para el mieloma latente de alto riesgo (SMM) December 11, 2019 ASH Minimal Residual Disease Evaluation By Multiparameter Flow Cytometry and Next Generation Sequencing in the Forte Trial December 11, 2019 ASH Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM) December 11, 2019 ASH Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor December 11, 2019 ASH Progression-Free Survival Analysis of Denosumab Vs Zoledronic Acid in Intent to Transplant Multiple Myeloma Patients Based on Treatment Regimen and Baseline Characteristics December 10, 2019 ASH Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma December 10, 2019 ASH Outcomes in Multiple Myeloma Based on Comorbidities and Race December 9, 2019 ASH B-Cell Maturation Antigen (BCMA) 2+1 T-Cell Engager CC-93269 in Patients with Relapsed Refractory Multiple Myeloma December 9, 2019 ASH Top Promising Multiple Myeloma Research Presented at ASH 2019 December 9, 2019 ASH New and Promising Clinical Trials Presented at ASH 2019 December 7, 2019 ASH Load More
